Keio University and Fujita Health University in Japan are set to commence the world's first clinical trial using a bio 3D printer to simultaneously repair knee bone and cartilage.
Researchers from Keio University and Fujita Health University are preparing to launch a groundbreaking clinical trial in July focused on regenerating knee joints. This trial will utilize a bio 3D printer to simultaneously create and implant structures that repair both the bone and cartilage of the knee.
The technology aims to address injuries and degenerative conditions affecting the knee, which often involve damage to both the skeletal and cartilaginous tissues. Current treatments may address one tissue type but struggle to effectively regenerate both simultaneously, leading to incomplete recovery or long-term functional limitations.
By employing a bio 3D printer, the research team intends to construct a scaffold that mimics the complex architecture of the knee joint. This scaffold will be engineered to support the growth of both bone cells and cartilage cells, promoting their integration and the restoration of joint function. The simultaneous regeneration of both tissues is a key innovation of this approach.
The successful outcome of this clinical trial could represent a significant advancement in regenerative medicine and orthopedic surgery, offering new hope for patients suffering from debilitating knee injuries and osteoarthritis. This pioneering work underscores the growing potential of additive manufacturing in complex biological applications.
This development highlights the increasing sophistication of bio-3D printing for complex tissue regeneration. The ability to simultaneously print and repair both bone and cartilage in a load-bearing joint like the knee is a significant technical hurdle overcome. It moves beyond single-tissue printing, paving the way for more comprehensive regenerative solutions and potentially reducing the need for multiple surgeries or the use of artificial implants.
Edited by the news editor with AI and translated into English from the original report — please refer to the original source.